Eton Pharmaceuticals, Inc. — Q3 2022 Form 10-Q
Reporting period: Three and nine months ended September 30, 2022. Unaudited financial statements; dollar amounts below are USD millions unless stated otherwise.
Business context
Eton develops, acquires, and commercializes prescription products, with a focus on rare diseases. Its commercial products included ALKINDI SPRINKLE, Carglumic Acid, and Betaine Anhydrous; it also reported three late-stage development candidates. The company receives royalties or milestone payments on licensed products.
Financial performance and liquidity
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Revenue | $3.219 | $0.775 | $12.753 | $15.739 |
| Gross profit (margin) | $2.018 (62.7%) | $0.121 (15.6%) | $7.958 (62.4%) | $13.284 (84.4%) |
| Operating expenses | $4.913 | $5.968 | $17.280 | $16.093 |
| Operating loss | $(2.895) | $(5.847) | $(9.322) | $(2.809) |
| Net loss | $(3.045) | $(6.094) | $(9.933) | $(2.994) |
| Basic and diluted loss per share | $(0.12) | $(0.24) | $(0.40) | $(0.12) |
- Q3 revenue was entirely product sales and royalties. Nine-month revenue included $5.0 million licensing revenue from the Dr. Reddy’s transaction; 2021 included $14.0 million in licensing revenue.
- At September 30, cash and cash equivalents were $13.378 million, down from $14.406 million at December 31, 2021. Working capital was $11.8 million; current assets were $16.420 million and current liabilities $4.661 million.
- Nine-month operating cash flow was positive $1.981 million, compared with $0.396 million in 2021. Investing cash flow was negative $2.776 million, including the $2.0 million Betaine Anhydrous rights purchase; financing cash flow was negative $0.233 million. Cash declined by $1.028 million over the period.
- Debt carrying value was $6.386 million, including $0.708 million current and $5.678 million long-term, net of discount. The SWK loan is secured by company assets. An April 2022 amendment deferred principal payments until May 2023 and reduced the interest rate to three-month LIBOR plus 8%, subject to a 2% floor.
Material changes and notable items
- Q3 revenue rose $2.444 million year over year, primarily reflecting higher product sales and royalties. Nine-month revenue fell $2.986 million, as higher product sales and royalties did not offset the decrease in licensing revenue.
- Q3 operating loss narrowed year over year, but the nine-month operating loss widened, reflecting lower gross profit and higher G&A. Nine-month R&D declined to $3.052 million from $5.554 million; G&A increased to $14.228 million from $10.539 million.
- In June, Eton sold rights to Cysteine Hydrochloride, Biorphen, and Rezipres to Dr. Reddy’s for $5.0 million at closing and may receive up to an additional $45.0 million based on specified event and sales milestones. The filing does not establish that these contingent payments will be achieved.
- In September, Eton acquired U.S. marketing rights to FDA-approved Betaine Anhydrous for $2.0 million, with up to $1.0 million in commercial milestones. It also continued selling existing Biorphen inventory through year-end 2022 under the sale arrangement.
- Management believed cash, approved-product revenue, and additional milestones expected in 2022 would fund operations and capital needs for at least 12 months from the filing date. This is based on sales and spending assumptions; management cautioned cash could be used sooner and additional financing may be needed.
Outlook, risks, and other disclosures
- No quantified revenue, earnings, or product-launch guidance was provided. Development and regulatory outcomes for pipeline candidates, product sales growth, and milestone receipts remain uncertain.
- Management warned that slower sales growth, development delays, or failure to obtain regulatory approvals could require additional financing or a reduction or discontinuation of operations. Financing may be unavailable or dilutive; the SWK debt agreement also restricts certain actions, including dividends.
- Potential milestone revenue includes up to $25.0 million from Azurity products and up to $45.0 million from the Dr. Reddy’s transaction, subject to contractual milestones. These are contingent opportunities, not assured proceeds.
- The filing reported no pending or threatened litigation expected to materially affect operations and no material subsequent events. Management concluded disclosure controls were effective and reported no material change in internal control over financial reporting.
Important facts for investors to verify
- Whether commercial product sales and royalties can grow enough to support operations after the one-time licensing revenue and product-rights sale.
- Timing and likelihood of Dr. Reddy’s and Azurity milestone payments, and any associated escrow or partner-sharing obligations.
- Cash burn, working-capital requirements, and whether management’s stated 12-month liquidity outlook remains valid.
- SWK debt repayment schedule, interest-rate exposure, covenants, and any change to the LIBOR reference rate.
- Development, regulatory, and commercialization progress for the late-stage candidates and the associated funding needs.